Dishman Carbogen back on investor radar amid hopes of recovery

After reporting a drop in revenue and a net loss for FY21, the company is expected to benefit from high potential new molecules that are currently under the late phase three clinical trial.

https://ift.tt/3aexsgK

Post a Comment

0 Comments